ArticleProceedings of the National Academy of Sciences of the United States of America2024
Somatic mutations in tumor-infiltrating lymphocytes impact on antitumor immunity.
Abstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Fisher Information Limits on Genetic Stability, Diversity, and Regulation.Bulletin of mathematical biology · 2026Article
- Uncovering ectopic GC-like niches for tumor reactive lymphocyte priming in lung adenocarcinoma using Stereo-XCR-seq.Nature communications · 2026Article
- Comprehensive multi-omics analysis reveals prognostic, immune, and therapeutic signatures of TNFAIP family genes in breast cancer.PloS one · 2026Article
- Base-editing a single missense mutation in A20 enhances CAR-T cell efficacy.bioRxiv : the preprint server for biology · 2025Article
- Clonal hematopoiesis in myeloid malignancies and solid tumors.Nature cancer · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Fumiaki Mukohara *Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan.ORCID 0009-0000-8866-0684
Kazuma Iwata *Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan.
Takamasa IshinoDepartment of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan.
Takashi InozumeDepartment of Dermatology, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.ORCID 0000-0001-7054-1863
Joji NagasakiDepartment of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan.
Youki UedaDepartment of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan.ORCID 0000-0002-2627-8524
Ken SuzawaDepartment of General Thoracic Surgery and Breast and Endocrinological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama University, Okayama 700-8558, Japan.
Toshihide UenoDivision of Cellular Signaling, National Cancer Center Research Institute, Chuo-ku, Tokyo 104-0045, Japan.ORCID 0000-0002-7408-7298
Hideki IkedaDivision of Cell Therapy, Chiba Cancer Research Institute, Chiba 260-8717, Japan.ORCID 0009-0000-1334-7597
Katsushige KawaseDivision of Cell Therapy, Chiba Cancer Research Institute, Chiba 260-8717, Japan.ORCID 0000-0001-6998-8481
Yuka SaekiDepartment of Dermatology, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.ORCID 0009-0008-0120-6664
Shusuke KawashimaDepartment of Dermatology, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.ORCID 0000-0001-6628-4331
Kazuo YamashitaKOTAI Biotechnologies, Inc., Osaka 565-0871, Japan.
Yu KawaharaDepartment of Dermatology, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.
Yasuhiro NakamuraDepartment of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama 350-1298, Japan.ORCID 0000-0002-3664-5818
Akiko Honobe-TabuchiDepartment of Dermatology, University of Yamanashi, Yamanashi 409-3898, Japan.
Hiroko WatanabeDepartment of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan.ORCID 0009-0003-7020-3065
Hiromichi DansakoDepartment of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan.ORCID 0000-0002-2353-3024
Tatsuyoshi KawamuraDepartment of Dermatology, University of Yamanashi, Yamanashi 409-3898, Japan.ORCID 0000-0003-4008-2322
Yutaka SuzukiDepartment of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Chiba 277-8568, Japan.ORCID 0000-0003-4852-1879
Hiroaki HondaDepartment of Pathology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo 162-8666, Japan.ORCID 0000-0002-4617-9670
Hiroyuki ManoDivision of Cellular Signaling, National Cancer Center Research Institute, Chuo-ku, Tokyo 104-0045, Japan.
Shinichi ToyookaDepartment of General Thoracic Surgery and Breast and Endocrinological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama University, Okayama 700-8558, Japan.
Masahito KawazuDivision of Cell Therapy, Chiba Cancer Research Institute, Chiba 260-8717, Japan.ORCID 0000-0003-4146-3629
Yosuke TogashiDepartment of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan.ORCID 0000-0001-9910-0164
Funding
Astellas Foundation for Research on Metabolic Disorders N/AJapan Agency for Medical Research and Development (AMED) 21cm0106383Japan Agency for Medical Research and Development (AMED) 22ama221303h0001Japan Agency for Medical Research and Development (AMED) 22gm1810002s0101Japan Agency for Medical Research and Development (AMED) 23ck0106724Japan Agency for Medical Research and Development (AMED) JP22ck0106775h0001Japan Agency for Medical Research and Development (AMED) JP22zf0127009MEXT | Japan Science and Technology Agency (JST) JPMJAX2321MEXT | Japan Science and Technology Agency (JST) JPMJFR2049MEXT | Japan Society for the Promotion of Science (JSPS) 21H02772MEXT | Japan Society for the Promotion of Science (JSPS) 21H05051MEXT | Japan Society for the Promotion of Science (JSPS) 22K0824MEXT | Japan Society for the Promotion of Science (JSPS) 22K15472MEXT | Japan Society for the Promotion of Science (JSPS) 22K1945904MEXT | Japan Society for the Promotion of Science (JSPS) 22K20824MEXT | Japan Society for the Promotion of Science (JSPS) 23KK0419MSD Life Science Foundation, Public Interest Incorporated Foundation (SD Life Science Foundation) N/ANaito Foundation () N/ANational Cancer Center Research and Development Fund 2023-A-05Princess Takamatsu Cancer Research Fund N/ATakeda Science Foundation (TSF) N/A
Abstract
Immune checkpoint inhibitors (ICIs) exert clinical efficacy against various types of cancers by reinvigorating exhausted CD8
Indexed as
CD8-Positive T-LymphocytesLymphocytes, Tumor-InfiltratingTumor Necrosis Factor alpha-Induced Protein 3AnimalsFemaleHumansImmune Checkpoint InhibitorsMelanomaMiceMice, KnockoutMutationImmune Checkpoint InhibitorsTNFAIP3 protein, humanTumor Necrosis Factor alpha-Induced Protein 3cancer immunologysomatic mutationT celltumor-infiltrating lymphocytes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.